The influence of different combinations of cardiometabolic risk factors on the prevalence of MASLD and risk of advanced fibrosis deserves attention

J Hepatol. 2024 Feb;80(2):e82-e85. doi: 10.1016/j.jhep.2023.09.030. Epub 2023 Oct 7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Attention*
  • Cardiometabolic Risk Factors*
  • Prevalence